Technical Analysis for MRSN - Mersana Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 15.44 -1.40% -0.22
MRSN closed down 1.4 percent on Wednesday, January 17, 2018, on 2.19 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical MRSN trend table...

Date Alert Name Type % Chg
Jan 17 Shooting Star Candlestick Bearish 0.00%
Jan 17 Slingshot Bearish Bearish Swing Setup 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Oversold Stochastic Weakness 0.00%
Jan 16 Stochastic Buy Signal Bullish -1.40%
Jan 16 Volume Surge Other -1.40%
Jan 16 Doji - Bullish? Reversal -1.40%
Jan 16 Wide Bands Range Expansion -1.40%
Jan 16 Lower Bollinger Band Touch Weakness -1.40%
Jan 16 Oversold Stochastic Weakness -1.40%

Older signals for MRSN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.
Is MRSN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.01
52 Week Low 12.71
Average Volume 69,635
200-Day Moving Average 0.0
50-Day Moving Average 17.1468
20-Day Moving Average 16.6595
10-Day Moving Average 16.182
Average True Range 1.3082
ADX 12.09
+DI 14.25
-DI 17.31
Chandelier Exit (Long, 3 ATRs ) 15.7654
Chandelier Exit (Short, 3 ATRs ) 18.5146
Upper Bollinger Band 18.3309
Lower Bollinger Band 14.9881
Percent B (%b) 0.14
BandWidth 20.065428
MACD Line -0.4537
MACD Signal Line -0.2874
MACD Histogram -0.1663
Fundamentals Value
Market Cap 350.69 Million
Num Shares 22.7 Million
EPS -16.23
Price-to-Earnings (P/E) Ratio -0.95
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.21
Resistance 3 (R3) 17.33 16.87 16.92
Resistance 2 (R2) 16.87 16.42 16.81 16.82
Resistance 1 (R1) 16.15 16.14 15.92 16.03 16.72
Pivot Point 15.69 15.69 15.57 15.63 15.69
Support 1 (S1) 14.97 15.24 14.74 14.85 14.16
Support 2 (S2) 14.51 14.96 14.45 14.06
Support 3 (S3) 13.79 14.51 13.97
Support 4 (S4) 13.67